Ptc Therapeutics (PTCT) Non-Current Debt (2012 - 2025)

Ptc Therapeutics' Non-Current Debt history runs 12 years deep, the most recent figure standing at $286.0 million for Q2 2025.

• On a quarterly basis, Non-Current Debt changed 0.42% year-over-year to $286.0 million in Q2 2025; TTM through Jun 2025 was $286.0 million, a 0.42% change from a year earlier, with the FY2024 full-year figure at $285.4 million, changed 0.42% from the prior year.
• Non-Current Debt was little changed at $286.0 million in Q2 2025 per PTCT's latest filing, from $285.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $573.2 million in Q3 2023 and bottomed at $281.6 million in Q3 2021.
• The 5-year median for Non-Current Debt is $285.3 million (2024), against an average of $364.3 million.
• Across the five-year window, Non-Current Debt surged 102.81% in 2022 and plunged 50.29% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $281.9 million in 2021, then surged by 102.81% to $571.7 million in 2022, then plunged by 50.29% to $284.2 million in 2023, then gained by 0.42% to $285.4 million in 2024, then rose by 0.21% to $286.0 million in 2025.
• Per Business Quant, the three latest PTCT Non-Current Debt figures stand at $286.0 million (Q2 2025), $285.7 million (Q1 2025), and $285.4 million (Q4 2024).